表紙
市場調査レポート

大鵬薬品工業 - 製品パイプライン分析

Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 240941
出版日 ページ情報 英文 52 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
大鵬薬品工業 - 製品パイプライン分析 Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 52 Pages
概要

大鵬薬品工業は日本に本社を置く製薬企業で、アレルギー、免疫系疾患、癌、泌尿器疾患の領域に対する医薬品、抗アレルギー剤、抗がん剤、H2受容体アンタゴニストなどの製品を取り扱っています。

当レポートでは、大鵬薬品工業における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

大鵬薬品工業 の基本情報

  • 大鵬薬品工業 の概要
  • 主要情報
  • 企業情報

大鵬薬品工業 :R&Dの概要

  • 主な治療範囲

大鵬薬品工業 :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ

大鵬薬品工業 :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

大鵬薬品工業 :薬剤プロファイル

  • (tegafur + gimeracil + oteracil + calcium folinate)
  • (tegafur + gimeracil + oteracil)
  • bilastine
  • TAS-120
  • TAS-114
  • TAS-115
  • TAS-116
  • TAS-117
  • TAS-119
  • TAS-121
  • TAS-205
  • TAS-2913
  • TAS-2985
  • TAS-5567
  • Small Molecules to Inhibit S100B-p53 Interaction for Cancer

大鵬薬品工業 :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

大鵬薬品工業 :最新のパイプライン情報

大鵬薬品工業 :開発休止中のプロジェクト

大鵬薬品工業 :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル

大鵬薬品工業 :企業理念

大鵬薬品工業 :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07523CDB

Summary

Global Markets Direct's, 'Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Taiho Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Taiho Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Taiho Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Taiho Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Taiho Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Taiho Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Taiho Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Taiho Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Taiho Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Taiho Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Taiho Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Taiho Pharmaceutical Co., Ltd. Snapshot
    • Taiho Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Taiho Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Taiho Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Taiho Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Taiho Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Taiho Pharmaceutical Co., Ltd. - Drug Profiles
    • (tegafur + gimeracil + oteracil + calcium folinate)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (tegafur + gimeracil + oteracil)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bilastine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAS-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAS-114
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAS-115
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAS-116
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAS-117
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAS-119
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAS-121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAS-205
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAS-2913
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAS-2985
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAS-5567
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit S100B-p53 Interaction for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Taiho Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • Taiho Pharmaceutical Co., Ltd. - Dormant Projects
  • Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • (tegafur + gimeracil + oteracil)
      • orantinib
  • Taiho Pharmaceutical Co., Ltd. - Company Statement
  • Taiho Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Taiho Pharmaceutical Co., Ltd., Key Information
  • Taiho Pharmaceutical Co., Ltd., Key Facts
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2015
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015
  • Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
  • Taiho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Taiho Pharmaceutical Co., Ltd. - Phase III, 2015
  • Taiho Pharmaceutical Co., Ltd. - Phase I, 2015
  • Taiho Pharmaceutical Co., Ltd. - Preclinical, 2015
  • Taiho Pharmaceutical Co., Ltd. - Discovery, 2015
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Target, 2015
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2015
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2015
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Taiho Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2015
  • Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2015
  • Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2015
  • Taiho Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top